Stoke Therapeutics (STOK) and Biogen (BIIB) announced that the first patient has been dosed in the global Phase 3 EMPEROR study of zorevunersen for the treatment of Dravet syndrome. Zorevunersen, an investigational antisense oligonucleotide, has the potential to be the first disease-modifying treatment for Dravet syndrome.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STOK:
- Biogen, Stoke announce first patient dosed in Phase 3 EMPEROR study
- STOK Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Stoke Therapeutics initiated with a Buy at Jefferies
- Stoke Therapeutics’ EMPEROR Study: A New Hope for Dravet Syndrome
- Buy Rating for Stoke Therapeutics: Promising Dravet Syndrome Treatment Shows Significant Improvements